Aeglea Bio Therapeutics Inc(AGLE) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Current Price

$7.24

RSI

25.465

Beta:

1.683667

November 05, 2020
5.3M
-18.1M

16.409 %
-5.563 %

$0
$3,888,000
$5,205,000
$4,628,000
$6,085,000
-Infinity %
-33.873 %
12.468 %
-31.482 %

$-78,254,000
$-44,348,000
$-27,236,000
$-21,698,000
$-11,295,000
-43.328 %
-38.586 %
-20.333 %
-47.945 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.